[3] In 2016, she cofounded Relay Therapeutics,[4] a Massachusetts-based drug research company studying the motion of proteins using genomic data and computational biology.
[8] Born in Halle, a town in former East Germany, to parents Gerhard and Gertraude Hübner, she was an energetic child who began learning to play basketball as early as age seven.
Along with her father and husband, Kern published a paper on Vitamin B1 enzyme activation and was able to record the process unfolding utilizing a combination of NMR spectroscopy, X-ray crystallography, and biological computing.
[9] This granted Kern notability in the scientific community and ultimately paved the way for her tenure at Brandeis University where she continued her investigation of protein movement.
[17] The goal of MOMA Therapeutics is to develop new drugs using the knowledge of molecular machines, protein conformational changes, and enzyme-substrate interaction in order to deliver medications more precisely.